IgE monoclonal gammopathy: A case report and literature review

Immunoglobulin E (IgE) gammopathy is a rare disorder, accounting for just 0.1% of all patients with multiple myeloma (MM). Herein, we report a case of IgE monoclonal gammopathy without any biological and clinical symptoms, and we review 63 published cases in the literature. Demographic, biological a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2018-01, Vol.51, p.103-109
Main Authors: Hejl, C., Mestiri, R., Carmoi, T., Bugier, S., Chianea, D., Renard, C., Vest, P.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Electrophoresis, Capillary
Female
Gammopathy
Humans
Immunoglobulin E
Immunoglobulin E - blood
Male
MGUS
Middle Aged
Myeloma
Paraproteinemias - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunoglobulin E (IgE) gammopathy is a rare disorder, accounting for just 0.1% of all patients with multiple myeloma (MM). Herein, we report a case of IgE monoclonal gammopathy without any biological and clinical symptoms, and we review 63 published cases in the literature. Demographic, biological and clinical presentations and features appear to be similar to those of other subtypes of MM, with a median age of diagnosis of 67years. There is a slight excess of male patients, and incidence seems to increase with age. The prevalence of renal failure, anaemia and hypercalcaemia at diagnosis was computed to be at 26%, 44% and 18%, respectively, in patients with MM. According to the literature, IgE MM is more aggressive and associated with poorer survival. Nonetheless, cases that are prolonged have also been described. •A case of IgE monoclonal gammopathy is reported.•This case has been compared with 63 published cases in literature from 1967 to 2017.•The epidemiology of IgE variants seems to be similar to those of other myelomas.•The clinical and biological presentations also appear to be similar.•Prognosis and survival seem to be poorer than with other myelomas.
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2017.09.015